Unspecified tumor-selective metabolic enzyme target

The term "Unspecified tumor-selective metabolic enzyme target" refers to a generalized category of enzymes that are differentially regulated in cancer cells to support their unique bioenergetic and biosynthetic requirements (Hanahan & Weinberg, 2011). These enzymes are central to metabolic reprogramming, a hallmark of cancer, which includes shifts toward aerobic glycolysis, increased glutaminolysis, and enhanced lipid synthesis (Vander Heiden et al., 2009). By targeting enzymes that are specifically overexpressed or uniquely active in the tumor microenvironment, researchers aim to develop therapies that selectively kill cancer cells while sparing normal tissues. Examples of specific targets within this broad class include lactate dehydrogenase A (LDHA), glutaminase (GLS), and fatty acid synthase (FASN). Because this entry does not specify a particular protein or gene, it cannot be linked to specific clinical candidates or approved drugs. However, the concept remains a cornerstone of modern oncology drug discovery, focusing on the metabolic vulnerabilities created by oncogenic signaling.

Not applicable for an unspecified target.